China Approves Trastuzumab Deruxtecan (ENHERTU) Followed by THP for Neoadjuvant HER2-Positive Breast Cancer Based on DESTINY-Breast11 - Oncodaily

2026-03-29 - 02:19

China Approves Trastuzumab Deruxtecan (ENHERTU) Followed by THP for Neoadjuvant HER2-Positive Breast Cancer Based on DESTINY-Breast11 Oncodaily